NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...
atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant ...
Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results